Apabetalone (RVX-208) may lower CVD events in diabetes mellitus by affecting complement pathway and microbiome activity. (August 2017) - Kulikowski, Ewelina; Calosing, Cyrus; Tsujikawa, Laura; Wasiak, Sylwia; Gilham, Dean; Halliday, Christopher; Johansson, Jan; Sweeney, Michael; Wong, Norman